Teva recalls one lot of leukemia med after finding particulates in vial

Particulate contamination of injectable drugs isn’t just a hindrance for manufacturers and customers: it can pose serious health risks, too. And when those drugs are intended for cancer patients, the glitch becomes even more concerning.

Teva Pharmaceutical is pulling one lot of its injectable leukemia med IDArubicin hydrochloride in the U.S. after an internal inspection uncovered silica and iron oxide particulate matter in a lone drug vial, the company said in a recall notice published on the FDA’s website. The defect hasn’t turned up in any other vials, Teva added.